ClinicalTrials.gg
RecruitingNCT07235163Updated Aug 24, 2026

A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 Are Tolerated and Act in the Body of Healthy Adults

A Phase 1 interventional study of PF-08065010 and Placebo in Healthy, sponsored by Pfizer. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08065010) for possible treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

This study is seeking participants who are:

  • male or female between 18 and 65 years of age
  • deemed to be healthy

Participants in this study will receive PF-08065010 or placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-08065010 or placebo will be given as a shot (in the abdomen, thigh or back of the arms) or as an IV infusion in the arm (given directly into a vein) at the study clinic.

In Part A, participants will take PF-08065010 or placebo only 1 time and will take part in this study for about 5 months. During this time, they will stay at the study clinic for about 9-10 days and will have about 6 more study visits at the study clinic.

Participants in Part B of the study will take PF-08065010 or placebo once a month, for 3 months and will take part in this study for about 7 months. During this time, they will stay at the study clinic for about 4 days each month and will have about 6 more study visits at the study clinic.

During study clinic stays and study visits, urine, blood samples, and physical exams will be done.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female between 18 and 65 years of age
  • deemed to be healthy

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of medical conditions.
  2. History of (HIV) infection, , or ; positive testing for HIV, hepatitis B surface antigen (HBsAg)or hepatitis C antibody (HCVAb).
  3. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
  4. A positive urine drug test.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Part A: Cohort 3: single ascending dose (SAD)

    Dose C - Participants will receive PF-08065010 or placebo.

    Drug: PF-08065010 · Drug: Placebo

  • Experimental
    Part A: Cohort 8: single ascending dose (SAD)

    Optional Japanese Cohort dose to be determined - Participants will receive PF-08065010 or placebo.

    Drug: PF-08065010 · Drug: Placebo

  • Experimental
    Part A: Cohort 1: single ascending dose (SAD)

    Dose A - Participants will receive PF-08065010 or placebo.

    Drug: PF-08065010 · Drug: Placebo

  • Experimental
    Part A: Cohort 5: single ascending dose (SAD)

    Dose E - Participants will receive PF-08065010 or placebo.

    Drug: PF-08065010 · Drug: Placebo

  • Experimental
    Part A: Cohort 7: single ascending dose (SAD)

    Dose G - Participants will receive PF-08065010 or placebo.

    Drug: PF-08065010 · Drug: Placebo

  • Experimental
    Part A: Cohort 4: single ascending dose (SAD)

    Dose D - Participants will receive PF-08065010 or placebo.

    Drug: PF-08065010 · Drug: Placebo

  • Experimental
    Part A: Cohort 2: single ascending dose (SAD)

    Dose B - Participants will receive PF-08065010 or placebo.

    Drug: PF-08065010 · Drug: Placebo

  • Experimental
    Part A: Cohort 9: single ascending dose (SAD)

    Optional Chinese Cohort dose to be determined - Participants will receive PF-08065010 or placebo.

    Drug: PF-08065010 · Drug: Placebo

  • Experimental
    Part A: Cohort 6: single ascending dose (SAD)

    Dose F - Participants will receive PF-08065010 or placebo.

    Drug: PF-08065010 · Drug: Placebo

  • Experimental
    Part A: Cohort 10: single ascending dose (SAD)

    Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo.

    Drug: PF-08065010 · Drug: Placebo

  • Experimental
    Part A: Cohort 11: single ascending dose (SAD)

    Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo.

    Drug: PF-08065010 · Drug: Placebo

  • Experimental
    Part B: Cohort 12: multiple dose

    Dose F - Participants will receive PF-08065010 or placebo.

    Drug: PF-08065010 · Drug: Placebo

  • Experimental
    Part B: Cohort 13: multiple dose

    Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo.

    Drug: PF-08065010 · Drug: Placebo

  • Experimental
    Part B: Cohort 14: multiple dose

    Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo.

    Drug: PF-08065010 · Drug: Placebo

Interventions

  • DrugPF-08065010

    Experimental Pfizer compound which will be subcutaneous (SC) or intravenous (IV).

  • DrugPlacebo

    Placebo which will be SC or IV

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Part A

    Time frame: Baseline, approximately up to 5 months

  2. Number of Participants With Clinically Significant Laboratory Abnormalities

    Part A

    Time frame: Baseline, approximately up to 5 months

  3. Number of Participants With Vital Sign Abnormalities

    Part A

    Time frame: Baseline, approximately up to 5 months

  4. Number of Participants with Change from Baseline in Physical Exam (PE) Parameters

    Part A

    Time frame: Baseline, approximately up to 5 months

  5. Number of Participants with Change from Baseline in Electrocardiogram (ECG) Parameters

    Part A

    Time frame: Baseline, approximately up to 5 months

  6. Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Part B

    Time frame: Baseline, approximately up to 7 months

  7. Number of Participants With Clinically Significant Laboratory Abnormalities

    Part B

    Time frame: Baseline, approximately up to 7 months

  8. Number of Participants with Vital Sign Abnormalities

    Part B

    Time frame: Baseline, approximately up to 7 months

  9. Number of Participants with Change from Baseline in Physical Exam (PE) Parameters

    Part B

    Time frame: Baseline, approximately up to 7 months

  10. Number of Participants with Change from Baseline in Electrocardiogram (ECG) Parameters

    Part B

    Time frame: Baseline, approximately up to 7 months

Secondary outcomes

  1. Area Under the Plasma Concentration-time Profile from Time Zero to the Time of Last Quantifiable Concentration (AUClast)

    Part A

    Time frame: Predose (Day 1), approximately up to 5 months

  2. Area Under the Curve from Time Zero to Extrapolated Infinite Time (AUCinf)

    Part A

    Time frame: Predose (Day 1), approximately up to 5 months

  3. Maximum Observed Plasma Concentration (Cmax)

    Part A

    Time frame: Predose (Day 1), approximately up to 5 months

  4. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Part A

    Time frame: Predose (Day 1), approximately up to 5 months

  5. Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half.

    Part A

    Time frame: Predose (Day 1), approximately up to 5 months

  6. Area under the serum concentration time profile over the dosing interval of 28 days (AUCtau)

    Part B

    Time frame: Predose (Day 1), approximately up to 7 months

  7. Maximum Observed Plasma Concentration (Cmax)

    Part B

    Time frame: Predose (Day 1), approximately up to 7 months

  8. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Part B

    Time frame: Predose (Day 1), approximately up to 7 months

  9. Plasma Decay Half-Life (t1/2)

    Part B

    Time frame: Predose (Day 1), approximately up to 7 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 19, 2025
StartActual
Apr 21, 2026
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07235163
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Apr 21, 2026
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Aug 24, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion